Select recent larger real-world series on alloHCT for PTCLa
| . | CIBMTR/EBMT LY19-0124and EBMT (data on file) . | JSTCT21 . | GETH/GELTAMO30 . | SFGM-TC25 . | DSHNHL18 . | CIBMTR AITL26 . | CIBMTR 201320 . |
|---|---|---|---|---|---|---|---|
| Study type | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective |
| Eligibility | AITL/ALCL/NOS | AITL/NOS, R/R + HCT-naive only | Any + CTCL | Any | Any + T-LBL + T-PLL, MAC only | AITL, MRD and MUD only | AITL/ALCL/NOS |
| N (% AITL+ALCL+NOS) | 1942 (100%) | 312 (100%) | 201 (74%) | 285 (82%) | 84 (62%) | 249 (100%) | 126 (100%) |
| AITL | 31% | 36% | 21% | 29% | 20% | 100% | 10% |
| ALCL | 20% | - | 11% | 14% | 18% | - | 40% |
| PTCL-NOS | 50% | 64% | 41% | 39% | 36% | - | 50% |
| Period | 2008-2018 | 2006-2018 | 1995-2018 | 2006-2014 | 2003-2013 | 2000-2016 | 1996-2006 |
| Age (years; median [range]) | 52 (18-77) | 56/51 (16-73)c | 47 (17-69) | 50 (16-69) | 50 (17-74) | 56 (21-77) | 38 (5-60) |
| PS > 0 (ECOG) or <90% (Karnofsky) | 34% | NA | NA | NA | NA | 45% | 33% |
| HCT-CI ≥ 3 | 38% | 17% | 30% | NA | NA | 34% | NA |
| Prior lines/median (range) | 2 (1-NA)b | 3 (2-4) | 3 (1-7) | 2 (1-NA) | 3 (1-7) | 3 (1-5) | 3 (1 ≥ 3) |
| Prior autoHCT | 38% | - | 41% | 23% | 23% | 39% | NA |
| Disease status refractory | 19% | 54% | 14% | 11% | 43% | 21% | 32% |
| Conditioning regimen RIC | 66% | 60% | 74% | 62% | 0 | 73% | 36% |
| Nonrelapse mortality | |||||||
| 3 y | 22% | 31/33%c | 24% (2 y) | 23%d | 49% | 28% | 27%-32% |
| Relapse incidence | |||||||
| 3 y | 28% | 23/22%c | 24% | 20% | 14% | 20% | 32%-40% |
| Progression-free survival | |||||||
| 3 y | 50% | 46/40%c | 52% | >54% | 37% | 52% | 37% |
| 3 y (if refractory at HCT) | 36% | NA | NA | 35%. | NA | 38% | |
| Overall survival | |||||||
| 3 y | 62% | 52/52%c | 60% | 62% | 38% | 60% | 46% |
| Follow-up (mo) | 37 (1-134) | 44 | 49 (5-253) | 72 | 15 (2-114) | 49 (4-170) | 49 (3-157) |
| . | CIBMTR/EBMT LY19-0124and EBMT (data on file) . | JSTCT21 . | GETH/GELTAMO30 . | SFGM-TC25 . | DSHNHL18 . | CIBMTR AITL26 . | CIBMTR 201320 . |
|---|---|---|---|---|---|---|---|
| Study type | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective | Registry retrospective |
| Eligibility | AITL/ALCL/NOS | AITL/NOS, R/R + HCT-naive only | Any + CTCL | Any | Any + T-LBL + T-PLL, MAC only | AITL, MRD and MUD only | AITL/ALCL/NOS |
| N (% AITL+ALCL+NOS) | 1942 (100%) | 312 (100%) | 201 (74%) | 285 (82%) | 84 (62%) | 249 (100%) | 126 (100%) |
| AITL | 31% | 36% | 21% | 29% | 20% | 100% | 10% |
| ALCL | 20% | - | 11% | 14% | 18% | - | 40% |
| PTCL-NOS | 50% | 64% | 41% | 39% | 36% | - | 50% |
| Period | 2008-2018 | 2006-2018 | 1995-2018 | 2006-2014 | 2003-2013 | 2000-2016 | 1996-2006 |
| Age (years; median [range]) | 52 (18-77) | 56/51 (16-73)c | 47 (17-69) | 50 (16-69) | 50 (17-74) | 56 (21-77) | 38 (5-60) |
| PS > 0 (ECOG) or <90% (Karnofsky) | 34% | NA | NA | NA | NA | 45% | 33% |
| HCT-CI ≥ 3 | 38% | 17% | 30% | NA | NA | 34% | NA |
| Prior lines/median (range) | 2 (1-NA)b | 3 (2-4) | 3 (1-7) | 2 (1-NA) | 3 (1-7) | 3 (1-5) | 3 (1 ≥ 3) |
| Prior autoHCT | 38% | - | 41% | 23% | 23% | 39% | NA |
| Disease status refractory | 19% | 54% | 14% | 11% | 43% | 21% | 32% |
| Conditioning regimen RIC | 66% | 60% | 74% | 62% | 0 | 73% | 36% |
| Nonrelapse mortality | |||||||
| 3 y | 22% | 31/33%c | 24% (2 y) | 23%d | 49% | 28% | 27%-32% |
| Relapse incidence | |||||||
| 3 y | 28% | 23/22%c | 24% | 20% | 14% | 20% | 32%-40% |
| Progression-free survival | |||||||
| 3 y | 50% | 46/40%c | 52% | >54% | 37% | 52% | 37% |
| 3 y (if refractory at HCT) | 36% | NA | NA | 35%. | NA | 38% | |
| Overall survival | |||||||
| 3 y | 62% | 52/52%c | 60% | 62% | 38% | 60% | 46% |
| Follow-up (mo) | 37 (1-134) | 44 | 49 (5-253) | 72 | 15 (2-114) | 49 (4-170) | 49 (3-157) |
Selection criteria: actually transplanted patients only (not intent to transplant), publication year 2019 or earlier, containing at least 50 patients diagnosed with the main subsets (AITL, ALCL, or PTCL-NOS).
Of 765 patients with line information available.
Relapsed and primary refractory patients, respectively.
Estimated from published survival plot.
ALK−, ALK-negative; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; MAC, myeloablative conditioning; MRD, matched related donor; MUD, matched unrelated donor; NA, not available; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; T-LBL, T-lymphoblastic lymphoma; T-PLL, T-prolymphocytic leukemia.